Modulators of FPR1 and methods of using the same
View Patent ↗The disclosure provides at compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
1 . A compound of the following structural formula IIa:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein:
Z 1 is O and Z 2 is N, or Z 1 is N and Z 2 is O;
Ring A is an aromatic or non-aromatic ring, wherein:
X a and X b are each independently C, N, or a bond; and
X 1 , X 2 , X 3 , and X 4 are each independently C or N;
Ring B is an aromatic or non-aromatic ring, wherein:
Y a is C, N, or a bond; and
Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently C or N;
Ring C is selected from C 3 -C 12 carbocyclyl, 3 to 12-membered heterocyclyl, phenyl, and 5 to 10-membered heteroaryl;
R 1 , R 2 , and R 3 , for each occurrence, is independently selected from halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxy, —C(═O)(C 1 -C 6 alkyl), (C(═O)NR h R i , —NR h R i , —NR h C(═O)R k , —NR h C(═O)OR k , —NR h C(═O)NR i R j , —NR h S(═O) p R k , —OR k , —OC(═O)R k , —OC(═O)OR k , —OC(═O)NR h R i , —S(═O) p R k , —S(═O) p NR h R i , C 3 -C 12 carbocyclyl, 3 to 12-membered heterocyclyl, phenyl, and 5 to 10-membered heteroaryl; wherein:
the C 1 -C 6 alkyl, the C 2 -C 6 alkenyl, and the C 1 -C 6 alkoxy of any one of R 1 , R 2 , and R 3 and the C 1 -C 6 alkyl of —C(═O)(C 1 -C 6 alkyl) are each optionally substituted with 1 to 3 groups selected from halogen, cyano, —C(═O)R k , —C(═O)OR k , —C(═O)NR h R i , —NR h R i , —NR h C(═O)R k , —NR h C(═O)OR k , —NR h C(═O)NR i R i , —NR h s (═O) p R k , —OR k , —OC(═O)R k , —OC(═O)OR k , —OC(═O)NR h R i , —S(═O) p R k , —S(═O) p NR h R i , and C 3 -C 6 cycloalkyl;
the C 3 -C 12 carbocyclyl, the 3 to 12-membered heterocyclyl, the phenyl, the 5 to 10-membered heteroaryl of any one of R 1 , R 2 , and R 3 are each optionally substituted with 1 to 3 groups selected from halogen, cyano, C 1 -C 4 alkyl, —NR h R i , and —OR k ;
R h , R i , and R j , for each occurrence, are each independently selected from hydrogen, C 1 -C 4 alkyl, and C 3 -C 6 cycloalkyl; wherein:
the C 1 -C 4 alkyl of any one of R h , R i , and R j is optionally substituted with 1 to 3 groups selected from halogen, cyano, and —OH;
R k , for each occurrence, are each independently selected from hydrogen, C 1 -C 4 alkyl, and C 3 -C 6 cycloalkyl; wherein:
the C 1 -C 4 alkyl of any one of R h , R i , and R i is optionally substituted with 1 to 3 groups selected from halogen, cyano, and —OH;
k and m are each independently an integer selected from 0, 1, 2, 3, 4, 5, and 6;
n is an integer selected from 0, 1, 2, 3, 4, and 5; and
p is an integer selected from 1 and 2.
2 . The compound according to claim 1 , wherein the compound is of the following structural formula III:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein:
Ring A and Ring B are each an aromatic ring.
3 . The compound according to claim 1 , wherein the compound is of the following structural formula IV:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein:
no more than 3 of X a , X b , X 1 , X 2 , and X 3 are N; and
no more than 3 of Y a , Y 1 , Y 2 , Y 3 , and Y 4 are N.
4 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein:
no more than 2 of X a , X b , X 1 , X 2 , and X 3 are N; and
no more than 2 of Y a , Y 1 , Y 2 , Y 3 , and Y 4 are N.
5 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein:
X a and X b are each C or N; and
Y a is C or N.
6 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein Ring A is pyridinyl or pyrimidinyl substituted with k groups of R 1 .
7 . The compound according to claim 1 , wherein the compound is of the following structural formula V:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein X 1 is C or N.
8 . The compound according to claim 1 , wherein the compound is of the following structural formula VI:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing.
9 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein Ring C is C 5 -C 6 cycloalkyl or 5- to 6-membered heterocyclyl substituted with n groups of R 3 , wherein the 5- to 6-membered heterocyclyl optionally contains 1 or 2 heteroatoms selected from O and N.
10 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein Ring C is cyclohexyl or 6-membered heterocyclyl with n groups of R 3 , further wherein the 6-membered heterocyclyl contains 1 or 2 heteroatoms selected from O and N.
11 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein Ring C is tetrahydro-2H-pyranyl substituted with n groups of R 3 .
12 . The compound according to claim 1 , wherein the compound is of the following structural formula VII:
a tautomer thereof, a deuterated derivative of the compound or the tautomer, or a pharmaceutically acceptable salt of the foregoing, wherein:
Ring A and Ring B are each an aromatic ring;
no more than 3 of X a , X b , X 1 , X 2 , and X 3 are N; and
no more than 3 of Y a , Y 1 , Y 2 , Y 3 , and Y 4 are N.
13 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 12 , wherein:
no more than 2 of X a , X b , X 1 , X 2 , and X 3 are N; and
no more than 2 of Y a , Y 1 , Y 2 , Y 3 , and Y 4 are N.
14 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to any one of claim 12 , wherein:
X a and X b are each C or N; and
Y a is C or N.
15 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 12 , wherein Ring A is pyridinyl or pyrimidinyl substituted with k groups of R 1 .
16 . The compound, tautomer, deuterated derivative, prordrug, or pharmaceutically acceptable salt according to claim 1 , wherein Ring B is phenyl substituted with m groups of R 2 .
17 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 1 , R 2 , and R 3 , for each occurrence, is independently selected from halogen, cyano, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, —C(═O)(C 1 -C 6 alkyl), —C(═O)NR h R i , —NR h R i , —OR k , —S(═O) 2 R k , —S(═O) 2 NR h R i , C 3 -C 6 cycloalkyl, 5 to 6-membered heterocyclyl, phenyl, and 5 to 6-membered heteroaryl; wherein:
the C 1 -C 6 alkyl and the C 1 -C 6 alkoxy of any one of R 1 , R 2 , and R 3 and the C 1 -C 6 alkyl of —C(═O)(C 1 -C 6 alkyl) are each optionally substituted with 1 to 3 groups selected from halogen, cyano, C(═O)OR k , and —OR k ;
the C 3 -C 6 cycloalkyl, the 5 to 6-membered heterocyclyl, the phenyl, and the 5 to 6-membered heteroaryl of any one of R 1 , R 2 , and R 3 are each optionally substituted with 1 to 3 groups selected from halogen, cyano, C 1 -C 4 alkyl, and —OR k ;
R h and R i , for each occurrence, are each independently selected from hydrogen and C 1 -C 4 alkyl; wherein:
the C 1 -C 4 alkyl of any one of R h and R i is optionally substituted with 1 to 3 groups selected from halogen, cyano, and —OH; and
R k , for each occurrence, are each independently selected from hydrogen and C 1 -C 4 alkyl; wherein:
the C 1 -C 4 alkyl of any one of R h and R i is optionally substituted with 1 to 3 groups selected from halogen, cyano, and —OH.
18 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 1 , R 2 , and R 3 , for each occurrence, is independently selected from halogen, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —C(═O)(C 1 -C 4 alkyl), —C(═O)NR h R i , —NR h R i , and —OR k ; wherein:
the C 1 -C 4 alkyl and the C 1 -C 4 alkoxy of any one of R 1 , R 2 , and R 3 and the C 1 -C 4 alkyl of —C(═O)(C 1 -C 4 alkyl) are each optionally substituted is optionally substituted with 1 to 3 groups selected from halogen, cyano, and —OR k ;
R h and R i , for each occurrence, are each independently selected from hydrogen and C 1 -C 2 alkyl; and
R k , for each occurrence, are each independently selected from hydrogen and C 1 -C 2 alkyl.
19 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 1 , R 2 , and R 3 , for each occurrence, is independently selected from halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —C(═O)(C 1 -C 4 alkyl), and —OR k ; wherein:
the C 1 -C 4 alkyl of any one of R 1 , R 2 , and R 3 is optionally substituted is optionally substituted with 1 to 3 groups of halogen; and
R k , for each occurrence, are each independently selected from hydrogen and C 1 -C 2 alkyl.
20 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 1 , for each occurrence, is independently selected from F, Cl, Br, C 1 -C 2 alkyl, and —OR k ; wherein:
the C 1 -C 2 alkyl of R 1 is optionally substituted is optionally substituted with 1 to 3 groups of halogen; and
R k , for each occurrence, are each independently selected from hydrogen and C 1 -C 2 alkyl.
21 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 1 , for each occurrence, is independently selected from F, —CH 3 , and —OH.
22 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 2 , for each occurrence, is independently selected from F, Cl, Br, and C 1 -C 2 alkyl; wherein:
the C 1 -C 2 alkyl of R 1 is optionally substituted with 1 to 3 halogen.
23 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein R 2 , for each occurrence, is independently selected from Cl and —CF 3 .
24 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein k is an integer selected from 0, 1, and 2.
25 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein m is an integer selected from 1 and 2.
26 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein n is 0.
27 . The compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 , wherein the compound is selected from:
28 . A pharmaceutical composition comprising a compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 and at least one pharmaceutically acceptable carrier.
29 . A method of treating a disease, a disorder, or a condition mediated by the signaling of formyl peptide receptor 1 (FPR1) in a subject, comprising administering a therapeutically effective amount of a compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt according to claim 1 .
30 . The method according to claim 29 , wherein the disease, the disorder, or the condition is related to the CNS and is selected from stroke, dementia, Alzheimer's disease, Parkinson's disease, Picks disease, fronto-temporal dementia, vascular dementia, normal pressure hydrocephalus, epilepsy, seizure disorder, amyotrophic lateral sclerosis (ALS), spinal motor atrophies, Tay-Sach's, Sandoff disease, familial spastic paraplegia, spinocerebellar ataxia (SCA), Friedrich's ataxia, Wilson's disease, Menke's Sx, cerebral autosomal dominant arteriopathy with subcortical infarcts (CADASIL); spinal muscular atrophy, muscular dystrophies, Charcot Marie Tooth diseases, neurofibromatosis, von-Hippel Lindau, Fragile X, spastic paraplesia, tuberous sclerosis, Wardenburg syndrome, dystonias, benign essential tremor, tardive dystonia, tardive dyskinesia, Tourette's syndrome, ataxic syndromes, Shy Drager, Olivopontoicerebellar degeneration, striatonigral degenration, Gullian Barre syndrome, causalgia, complex regional pain syndrome types I and II, diabetic neuropathy, and alcoholic neuropathy, trigeminal neuropathy, trigeminal neuralgia, Menier's syndrome, glossopharangela neuralgia, dysphagia, dysphonia, cranial nerve palsies, myelopethies, traumatic brain injury, traumatic spinal injury, radiation brain injury, multiple sclerosis, post-menengitis syndrome, prion diseases, myelities, radiculitis, diabetes associated with dysproteinemias, transthyretin-induced neuropathies, neuropathy associated with HIV, neuropathy associated with Lyme disease, neuropathy associated with herpes zoster, carpal tunnel syndrome, tarsal tunnel syndrome, amyloid-induced neuropathies, leprous neuropathy, Bell's palsy, compression neuropathies, sarcoidosis-induced neuropathy, polyneuritis cranialis, heavy metal induced neuropathy, transition metal-induced neuropathy, drug-induced neuropathy, axonic brain damage, encephalopathies, chronic fatigue syndrome, and a malignant glioma.
31 . The method according to claim 29 , wherein the disease, the disorder, or the condition is stroke, wherein the stroke is selected from thrombotic stroke, embolic stroke, thromboembolic stroke, hemorrhagic stroke, venoconstrictive stroke, and venous stroke.
32 . The method according to claim 29 , wherein the disease, the disorder, or the condition is traumatic brain injury.
33 . The method according to claim 29 , wherein the disease, the disorder, or the condition is a malignant glioma.
34 . The method according to claim 33 , wherein the malignant glioma is selected from glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, anaplastic ependymoma, and anaplastic ganglioglioma.
35 . The method according to claim 34 , wherein the malignant glioma is glioblastoma.